Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Ultragenyx Pharmaceu (RARE)

Ultragenyx Pharmaceu (RARE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Ultragenyx Pharmaceu 60 Leveroni Court Novato CA 94949 USA

www.ultragenyx.com Employees: 1,371 P: 415-483-8800 F: 415-483-8810

Sector:

Medical

Description:

Ultragenyx Pharmaceutical Inc. is focused on the identification, acquisition, development and commercialization of novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases.

Key Statistics

Overview:

Market Capitalization, $K 2,105,736
Enterprise Value, $K 1,691,736
Shares Outstanding, K 98,307
Float, K 92,900
% Float 94.50%
Short Interest, K 9,932
Short Float 10.10%
Days to Cover 4.78
Short Volume Ratio 0.40
% of Insider Shareholders 5.50%
% of Institutional Shareholders 97.67%

Financials:

Annual Sales, $ 673,000 K
Annual Net Income, $ -575,000 K
Last Quarter Sales, $ 207,280 K
Last Quarter Net Income, $ -128,560 K
EBIT, $ -535,000 K
EBITDA, $ -504,000 K

Growth:

1-Year Return -37.57%
3-Year Return -45.92%
5-Year Return -79.30%
5-Year Revenue Growth 148.31%
5-Year Earnings Growth -10.42%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -1.29 on 02/12/26
Next Earnings Date 05/05/26
Earnings Per Share ttm -5.84
EPS Growth vs. Prev Qtr 28.73%
EPS Growth vs. Prev Year 7.19%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%

RARE Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -1,024.42%
Return-on-Assets % -43.10%
Profit Margin % -85.44%
Debt/Equity 0.00
Price/Sales 3.06
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share -0.83
Interest Coverage -8.21
60-Month Beta 0.25
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.